Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial

AIMS: This two‐part, double‐blind, double‐dummy, randomized, placebo‐controlled trial (83 sites) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed‐dose combinations (FDCs) in Japanese patients with type 2 diabetes mellitus (T2DM) who were poorly...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Obes Metab
Egile Nagusiak: Kaku, Kohei, Haneda, Masakazu, Tanaka, Yuko, Lee, Ganghyuck, Shiki, Kosuke, Miyamoto, Yuki, Solimando, Fernando, Lee, Jisoo, Lee, Christopher, George, Jyothis
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585831/
https://ncbi.nlm.nih.gov/pubmed/30091172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13496
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak